Upgrade to SI Premium - Free Trial

PTC Therapeutics (PTCT) PT Raised to $137 at Cantor Fitzgerald on ST-920 Acquisition

September 22, 2026 7:49 AM
Cantor Fitzgerald analyst Kristen Kluska raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $137.00 (from $130.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change